
Gastric Cancer- Pipeline Insight, 2025
Description
DelveInsight’s, “Gastric Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gastric Cancer: Overview
Gastric cancer, also known as stomach cancer, arises from the lining of the stomach. It is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths. The majority of gastric cancers are adenocarcinomas, which develop from the mucus-producing cells of the stomach lining. Risk factors include chronic gastritis, Helicobacter pylori infection, smoking, a diet high in salty and smoked foods, and genetic predispositions. Signs and symptoms of gastric cancer are often non-specific and may include weight loss, abdominal pain, nausea, vomiting, dysphagia (difficulty swallowing), early satiety (feeling full quickly), and melena (black, tarry stools indicating bleeding in the stomach). These symptoms often appear late in the disease, which is why gastric cancer is frequently diagnosed at an advanced stage.
The exact cause of gastric cancer is multifactorial. Chronic infection with H. pylori is a significant risk factor, leading to chronic inflammation and changes in the gastric mucosa that can progress to cancer. Genetic factors also play a role, with conditions like hereditary diffuse gastric cancer syndrome increasing risk. Environmental factors such as smoking, diet, and occupational exposure to certain chemicals also contribute.
Pathophysiologically, gastric cancer development involves a multistep process starting from chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and finally carcinoma. The interaction between genetic mutations and environmental factors leads to uncontrolled cell growth and tumor formation. Molecular changes such as alterations in the p53 gene, E-cadherin gene mutations, and other oncogene and tumor suppressor gene mutations are involved in the progression of the disease. Diagnosis of gastric cancer typically involves endoscopic examination and biopsy of suspicious lesions. Imaging studies such as CT scans, PET scans, and endoscopic ultrasound help in staging the disease. Treatment options depend on the stage of the cancer and may include surgery, chemotherapy, radiation therapy, and targeted therapy. Early-stage cancers may be treated with endoscopic resection or partial gastrectomy, while advanced cases often require a combination of treatments to manage the disease and improve quality of life. Immunotherapy has also shown promise in certain types of gastric cancer. Early detection and treatment are crucial for improving survival rates.
""Gastric Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastric Cancer Emerging Drugs
Further product details are provided in the report……..
Gastric Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.
Gastric Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Gastric Cancer: Overview
Gastric cancer, also known as stomach cancer, arises from the lining of the stomach. It is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths. The majority of gastric cancers are adenocarcinomas, which develop from the mucus-producing cells of the stomach lining. Risk factors include chronic gastritis, Helicobacter pylori infection, smoking, a diet high in salty and smoked foods, and genetic predispositions. Signs and symptoms of gastric cancer are often non-specific and may include weight loss, abdominal pain, nausea, vomiting, dysphagia (difficulty swallowing), early satiety (feeling full quickly), and melena (black, tarry stools indicating bleeding in the stomach). These symptoms often appear late in the disease, which is why gastric cancer is frequently diagnosed at an advanced stage.
The exact cause of gastric cancer is multifactorial. Chronic infection with H. pylori is a significant risk factor, leading to chronic inflammation and changes in the gastric mucosa that can progress to cancer. Genetic factors also play a role, with conditions like hereditary diffuse gastric cancer syndrome increasing risk. Environmental factors such as smoking, diet, and occupational exposure to certain chemicals also contribute.
Pathophysiologically, gastric cancer development involves a multistep process starting from chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and finally carcinoma. The interaction between genetic mutations and environmental factors leads to uncontrolled cell growth and tumor formation. Molecular changes such as alterations in the p53 gene, E-cadherin gene mutations, and other oncogene and tumor suppressor gene mutations are involved in the progression of the disease. Diagnosis of gastric cancer typically involves endoscopic examination and biopsy of suspicious lesions. Imaging studies such as CT scans, PET scans, and endoscopic ultrasound help in staging the disease. Treatment options depend on the stage of the cancer and may include surgery, chemotherapy, radiation therapy, and targeted therapy. Early-stage cancers may be treated with endoscopic resection or partial gastrectomy, while advanced cases often require a combination of treatments to manage the disease and improve quality of life. Immunotherapy has also shown promise in certain types of gastric cancer. Early detection and treatment are crucial for improving survival rates.
""Gastric Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gastric Cancer.
This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastric Cancer Emerging Drugs
- Tislelizumab: BeiGene
- Catumaxomab: Linton Pharm Co. Ltd.
- Tivumecirnon: RAPT Therapeutics
- DKN-01: Leap Therapeutics
- Venadaparib: Idience
- BDC-4182: Bolt Biotherapeutics
Further product details are provided in the report……..
Gastric Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastric Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.
Gastric Cancer Report Insights
- Gastric Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastric Cancer drugs?
- How many Gastric Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastric Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- BeiGene
- Linton Pharm Co. Ltd.
- RAPT Therapeutics
- Leap Therapeutics
- Idience
- Bolt Biotherapeutics
- Hubro Therapeutics
- Immunocore
- Ambrx
- Hangzhou DAC Biotech
- Beijing Immunoah Pharma Tech
- Base Therapeutics
- Nanjing KAEDI Biotech
- HiberCell
- Transcenta Holding
- Suzhou Zelgen Biopharmaceuticals
- Daiichi Sankyo
- Ipsen
- Alligator Bioscience
- Bristol Myers Squibb
- Jiangsu Hengrui Medicine
- Shanghai Junshi Biosciences
- ImmunoACT
- Tislelizumab
- Catumaxomab
- Tivumecirnon
- DKN-01
- Venadaparib
- BDC-4182
- FMPV-1
- IMC R117C
- ARX 788
- DX126 262
- ZWB 67
- NK 510
- KD 496
- HC 5404
- Osemitamab
- Donafenib
- Datopotamab deruxtecan
- Irinotecan sucrosofate
- HLX 22
- Ipilimumab
- Retlirafusp alfa
- Toripalimab
- HCAR 4
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Table of Contents
550 Pages
- Introduction
- Executive Summary
- Gastric Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Gastric Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Catumaxomab: Linton Pharm Co. Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Tivumecirnon: RAPT Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Venadaparib: Idience
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- BDC-4182: Bolt Biotherapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Gastric Cancer Key Companies
- Gastric Cancer Key Products
- Gastric Cancer- Unmet Needs
- Gastric Cancer- Market Drivers and Barriers
- Gastric Cancer- Future Perspectives and Conclusion
- Gastric Cancer Analyst Views
- Gastric Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.